Your browser is no longer supported. Please, upgrade your browser.
XLRN Acceleron Pharma Inc. weekly Stock Chart
XLRN [NASD]
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own0.50% Shs Outstand49.81M Perf Week5.87%
Market Cap2.14B Forward P/E- EPS next Y-1.85 Insider Trans-18.82% Shs Float45.17M Perf Month3.33%
Income-119.60M PEG- EPS next Q-0.43 Inst Own92.40% Short Float9.45% Perf Quarter-6.53%
Sales37.50M P/S57.11 EPS this Y3.50% Inst Trans1.18% Short Ratio15.24 Perf Half Y2.96%
Book/sh8.79 P/B4.89 EPS next Y20.30% ROA-28.00% Target Price57.42 Perf Year-16.29%
Cash/sh8.55 P/C5.03 EPS next 5Y- ROE-30.80% 52W Range37.01 - 56.91 Perf YTD-1.27%
Dividend- P/FCF- EPS past 5Y9.00% ROI-42.60% 52W High-24.45% Beta1.20
Dividend %- Quick Ratio14.00 Sales past 5Y-24.60% Gross Margin- 52W Low16.17% ATR1.87
Employees173 Current Ratio14.00 Sales Q/Q27.30% Oper. Margin- RSI (14)48.54 Volatility5.12% 4.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.30% Profit Margin- Rel Volume1.04 Prev Close44.64
ShortableYes LT Debt/Eq0.00 EarningsNov 06 BMO Payout- Avg Volume280.03K Price42.99
Recom2.00 SMA20-1.62% SMA500.58% SMA2000.50% Volume290,666 Change-3.69%
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Jun-13-17Downgrade Oppenheimer Outperform → Perform
May-17-17Initiated Goldman Sell $20
Mar-14-17Initiated JP Morgan Neutral
Mar-09-17Initiated UBS Buy $36
Mar-02-17Upgrade Citigroup Neutral → Buy
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
Nov-12-19 05:41AM  Edited Transcript of XLRN earnings conference call or presentation 6-Nov-19 3:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Nov-08-19 04:25PM  How Celgene Added A New Drug To Its Wheelhouse A Month Early Investor's Business Daily +6.57%
02:24PM  Celgene's rare disease drug gets FDA approval MarketWatch
02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
12:33PM  FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
Nov-06-19 09:05AM  Acceleron Pharma (XLRN) Reports Q3 Loss, Tops Revenue Estimates Zacks -15.43%
09:05AM  Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting Business Wire
07:53AM  Acceleron Reports Third Quarter 2019 Operating and Financial Results Business Wire
Oct-30-19 10:33AM  Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-19 07:00AM  Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019 Business Wire
Oct-27-19 01:57PM  Is Acceleron Pharma Inc (XLRN) Going to Burn These Hedge Funds? Insider Monkey
Oct-24-19 03:57PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
Oct-11-19 09:45AM  Geron Starts Enrollment in Phase III MDS Study on Imetelstat Zacks
Oct-10-19 03:16PM  One Thing To Remember About The Acceleron Pharma Inc. (NASDAQ:XLRN) Share Price Simply Wall St.
Oct-01-19 10:36AM  Geron's Imetelstat Gets Fast Track Status for Myelofibrosis Zacks
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
Sep-17-19 04:38PM  This Biotech Just Flopped On A Test; Why Analysts Remain Bullish Investor's Business Daily
08:40AM  Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock. Barrons.com
07:23AM  The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga
Sep-16-19 05:17PM  Acceleron Pharma stock down 4% after company halts treatment trial MarketWatch
04:30PM  Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy Business Wire
Sep-11-19 10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
Sep-10-19 06:00PM  FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-09-19 11:15AM  Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation Benzinga
07:00AM  Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension Business Wire
Sep-04-19 09:03PM  Edited Transcript of XLRN earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 10:18AM  Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why Zacks
Aug-20-19 08:52AM  Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque? Simply Wall St.
Aug-19-19 10:24AM  Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer Zacks
Aug-06-19 11:23AM  Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript Motley Fool
07:00AM  What You'll Want to Know About Acceleron Pharma's Q2 Update Motley Fool
Aug-05-19 05:45PM  Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.79%
04:05PM  Acceleron Reports Second Quarter 2019 Operating and Financial Results Business Wire
Jul-31-19 11:32AM  Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance Zacks
Jul-24-19 07:00AM  Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019 Business Wire
Jul-15-19 09:17AM  Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock? Simply Wall St.
Jun-26-19 07:35AM  Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension Business Wire
Jun-14-19 02:41PM  Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis Simply Wall St.
Jun-13-19 12:27PM  Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
Jun-10-19 07:00AM  Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis Business Wire
Jun-06-19 04:56PM  Celgene & Acceleron's BLA for Luspatercept Accepted by FDA Zacks
Jun-05-19 09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
Jun-04-19 04:24PM  Here's Another Checkmark For Bristol's Looming Celgene Takeover Investor's Business Daily
07:30AM  Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia Business Wire
May-28-19 10:11AM  Geron Stock Up More Than 50% in 2019 So Far: Here's Why Zacks
May-14-19 07:00AM  Acceleron to Present at the UBS Global Healthcare Conference Business Wire
May-09-19 07:15PM  Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:09PM  Acceleron: 1Q Earnings Snapshot Associated Press
04:05PM  Acceleron Reports First Quarter 2019 Operating and Financial Results Business Wire
May-08-19 10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
07:41AM  5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility Zacks
May-07-19 10:38AM  Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings? Zacks
05:53AM  Telenav (TNAV) to Report Q3 Earnings: What's in the Offing? Zacks
May-06-19 05:07AM  Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings? Zacks
May-01-19 07:00AM  Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019 Business Wire
Apr-29-19 09:58PM  Heres What Hedge Funds Think About Acceleron Pharma Inc (XLRN) Insider Monkey
Apr-26-19 01:44PM  Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales Zacks
07:30AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia Business Wire
Apr-15-19 02:03PM  If You Had Bought Acceleron Pharma (NASDAQ:XLRN) Shares Three Years Ago You'd Have Made 36% Simply Wall St.
Apr-12-19 01:03AM  Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Apr-08-19 06:11PM  Celgene & Acceleron Submit BLA for Luspatercept to the FDA Zacks
Apr-05-19 04:01PM  Acceleron Announces Departure of Chief Medical Officer Business Wire
09:28AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA Business Wire
07:48AM  The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership Benzinga
Mar-28-19 07:10AM  Factors of Influence in 2019, Key Indicators and Opportunity within The Ultimate Software Group, New Mountain Finance, Denny's, World Fuel Services, Agree Realty, and Acceleron Pharma New Research Emphasizes Economic Growth GlobeNewswire
Mar-05-19 07:00AM  Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease Business Wire
Mar-01-19 12:32PM  Acceleron Pharma Inc. (NASDAQ:XLRN): The Best Of Both Worlds Simply Wall St.
Feb-28-19 02:48AM  Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-27-19 04:05PM  Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Business Wire
Feb-26-19 04:01PM  Acceleron Pharma Is Ready to Rally Ahead of Earnings TheStreet.com +6.79%
Feb-20-19 01:16PM  Is Acceleron Pharma a Buy? Motley Fool
10:31AM  Earnings Preview: Acceleron Pharma (XLRN) Q4 Earnings Expected to Decline Zacks
Feb-19-19 07:00AM  Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019 Business Wire
Feb-13-19 07:00AM  Acceleron to Present at Two Upcoming Healthcare Investor Conferences Business Wire
Jan-31-19 11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Jan-29-19 10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-24-19 12:58PM  Celgene Buys More of This Biotech Stock Barrons.com
Jan-22-19 07:30AM  Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-16-19 07:00AM  Acceleron Announces Pricing of Public Offering of Common Stock Business Wire
Jan-14-19 04:04PM  Acceleron Announces Proposed Public Offering of Common Stock Business Wire
Jan-10-19 07:00AM  Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood Business Wire
Jan-08-19 05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
02:39PM  Here's Why Acceleron Pharma Fell 17.7% in December Motley Fool
Jan-02-19 07:00AM  Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-18 05:07PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Dec-21-18 09:00AM  How Financially Strong Is Acceleron Pharma Inc. (NASDAQ:XLRN)? Simply Wall St.
Dec-12-18 03:10AM  Is Acceleron Pharma Inc (XLRN) A Good Stock To Buy? Insider Monkey
Dec-05-18 04:30PM  Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for Best of ASH by the American Society of Hematology Business Wire
Dec-03-18 06:09PM  Celgene (CELG) Announces Various Cancer Data at ASH 2018 Zacks
07:30AM  Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-01-18 05:00PM  Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018 Business Wire
07:03AM  Top Biotech Stocks to Watch at ASH 2018 Motley Fool
Nov-28-18 07:00AM  Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease Business Wire
Nov-27-18 07:00AM  Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting Business Wire
Nov-26-18 07:00AM  Acceleron to Participate in Two Upcoming Healthcare Investor Conferences Business Wire
Nov-19-18 08:46PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Veness Adam MVP, General Counsel and Sec.Sep 10Sale45.2082437,24116,101Sep 10 08:25 PM
Kumar RavindraSVP & Chief Scientific OfficerSep 10Sale45.243,389153,31886,986Sep 10 08:24 PM
Quisel John DEVP, Chief Business OfficerSep 10Sale45.233,584162,10459,158Sep 10 08:23 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerSep 10Sale45.308,000362,40022,279Sep 10 08:22 PM
Dable Habib JCEO and PresidentSep 10Sale45.235,625254,41270,883Sep 10 08:21 PM
Veness Adam MVP, General Counsel and Sec.Aug 09Sale45.003,268147,06016,925Aug 12 04:18 PM
Veness Adam MVP, General Counsel and Sec.Jul 16Sale40.7153821,90220,193Jul 17 05:49 PM
Quisel John DEVP, Chief Business OfficerJul 09Option Exercise4.828,90842,90862,742Jul 11 04:26 PM
George JeanDirectorJun 28Sale41.1711,812486,3000Jun 28 07:25 PM
George JeanDirectorJun 26Option Exercise26.3537,500988,17541,250Jun 28 07:25 PM
George JeanDirectorJun 26Sale39.1625,6881,005,94215,562Jun 28 07:25 PM
Zakrzewski Joseph SDirectorJun 14Buy38.055,000190,25012,750Jun 17 06:08 PM
Quisel John DEVP, CBO and SecretaryApr 09Sale44.643,622161,67153,834Apr 11 04:58 PM
Kumar RavindraSVP & Chief Scientific OfficerApr 09Sale44.643,622161,67190,375Apr 11 04:58 PM
Dable Habib JCEO and PresidentApr 09Sale44.607,460332,74876,508Apr 11 04:58 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale44.6212,000535,40530,279Apr 11 04:58 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 02Sale48.0264831,11742,279Apr 04 06:07 PM
CELGENE CORP /DE/10% OwnerJan 18Buy43.00706,20630,366,8586,824,685Jan 22 05:00 PM
Dable Habib JCEO and PresidentJan 03Sale43.411,95784,96166,268Jan 04 06:34 PM
Quisel John DEVP, CBO and SecretaryJan 02Sale42.835,942254,49052,656Jan 04 06:35 PM
Kumar RavindraSVP & Chief Scientific OfficerJan 02Sale42.945,788248,54690,147Jan 04 06:36 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale42.805,712244,49438,227Jan 04 06:34 PM
Dable Habib JCEO and PresidentDec 04Sale52.9912,675671,61068,225Dec 06 04:22 PM